Health Affairs, 23, no. 1 (2004): 48-50 doi: 10.1377/hlthaff.23.1.48 © 2004 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Pammolli, F. Articles by Riccaboni, M. Search for Related Content PubMed PubMed Citation Articles by Pammolli, F. Articles by Riccaboni, M. Related Collections Pharmaceuticals Research And Technology

Industry Priorities

PERSPECTIVE

Market Structure And Drug Innovation

An explosion of knowledge and a growing array of tools and technologies have transformed modern drug R&D, while its cost has risen by a sizable amount. At the same time, the unchecked increase in health care and prescription drug spending has spawned cost containment policies that are restricting the demand for drugs in all major markets. This Perspective explores the interplay between technological advances and regulatory policies and their likely impact on the dynamics of the pharmaceutical industry.

                      What's this?

This article has been cited by other articles:

				J. H. Barton and E. J. Emanuel The Patents-Based Pharmaceutical Development Process: Rationale, Problems, and Potential Reforms JAMA, October 26, 2005; 294(16): 2075 - 2082. [Abstract] [Full Text] [PDF]